Open Access or Reputation Trap: What It Really Costs to Publish a Medtech Breakthrough in 2025

There is a number that tends to produce a long silence when mentioned to researchers who have not encountered it before: €9,500. That is the article processing charge — the fee paid by the author to make a paper freely available — at the upper end of Nature's open access pricing. It is not an outlier. APCs across the publishing landscape range from under $100 to over $10,000 depending on the journal, while an independent study estimated that the actual cost of efficiently publishing a scholarly article should be in the region of €200 to €1,000. The gap between what publishers charge and what publishing actually costs is not incidental. It is the business model.

For a medtech researcher preparing to publish a genuinely important result — a diagnostic platform, a novel device, a clinical study with commercial implications — the publishing decision is not merely an academic one. It is a strategic and financial one, with consequences that extend well beyond the paper itself into investor perception, regulatory credibility, and the long-term reputation of the science.

This article maps the actual cost landscape of open access publishing in biotech and medtech, explains how predatory journals have evolved to exploit it, and offers a practical framework for making publication decisions that serve the science rather than the publisher's profit margin.

What Open Access Actually Costs in 2025

The open access publishing model shifts the cost of making research freely readable from the reader — historically, the subscribing library — to the author, their institution, or their funder. In principle, this is a reasonable arrangement that increases the reach of published research. In practice, it has created a fee structure that bears almost no relationship to the actual cost of peer review and editorial processing.

A 2025 study examining APCs across 1,117 hybrid and fully open access journals across 29 medical specialties found significant variation, with haematology and oncology journals carrying the highest median APC at $4,690, while hybrid journals had higher median APCs than fully open access journals — $4,248 versus $2,909. For a medtech researcher whose work sits at the intersection of engineering and clinical medicine, the relevant journals frequently fall into the higher end of this range.

Here is a concrete comparison of what publication costs across the journals most relevant to the medtech and biotech space in 2025:

A 2019 analysis found that 75% of European spending on scientific journals goes to just five publishers: Elsevier, Springer Nature, Wiley, Taylor & Francis, and the American Chemical Society. Read-and-publish agreements negotiated between major publishers and national research consortia — including cOAlition S in Europe and national agreements in Israel through the Israeli Council for Higher Education — have reduced or eliminated APCs for researchers at member institutions. But coverage is uneven, and researchers at smaller institutions, early-stage startups, or clinical settings outside major university systems frequently find themselves outside these agreements and facing the full fee.

The EU and Israeli Funding Landscape

For researchers in Europe and Israel, the APC question is inseparable from the funder mandate question. Horizon Europe — the EU's primary research funding programme — requires that publications arising from funded research be made immediately open access. Crucially, Horizon Europe does not cover APCs for articles in hybrid open access journals — meaning that a researcher who publishes in a traditional subscription journal's open access option using Horizon funding may find the APC ineligible for reimbursement. The correct route for Horizon-funded researchers is fully open access journals or diamond open access (no APC at all), with institutional repositories as an alternative for embargo-compliant green open access.

In Israel, the Israel Science Foundation and the Israeli Innovation Authority have both moved toward open access mandates in recent years, with the ISF formally requiring open access for funded research. Israeli researchers at the major research universities — the Weizmann Institute, the Technion, the Hebrew University, Tel Aviv University — benefit from institutional agreements with major publishers that reduce or eliminate APCs. Researchers at smaller institutions, medical centres without full university status, or independent startup-affiliated researchers carry the full cost themselves.

The practical consequence for a medtech startup in Tel Aviv or Berlin that is preparing its first major clinical publication is this: the publishing budget needs to be planned as part of the research budget, not treated as an afterthought once the paper is accepted. A single paper in a high-impact journal, without institutional coverage, can cost more than a month's laboratory consumables.

How Predatory Journals Exploit This Landscape

Into this expensive and complicated landscape, predatory publishers have inserted themselves with considerable sophistication. The early predatory journals were easy to spot: obviously poor website design, blatant grammatical errors, absurd editorial claims. Modern predatory publishers have become far more sophisticated — some create professional-looking websites, mimic the appearance of legitimate journals, and use carefully crafted language that can deceive even experienced researchers without careful investigation.

The mechanics of the predatory journal business model exploit exactly the pressures that legitimate publishing has created. When APCs at reputable journals reach $5,000 or more, a $500 or $800 fee from a journal with a plausible name and a convincing website looks like a bargain. When career pressure demands publication and timelines are short, the promise of a two-week review cycle is attractive. When the distinction between a genuine open access journal and a predatory one is not immediately obvious, researchers under pressure make decisions that damage them for years.

Predatory journals typically have low or nonexistent academic standards for peer review, often accepting papers with little to no scrutiny. They may also charge exorbitant fees without providing the support or resources necessary to ensure high-quality publications, and engage in aggressive marketing tactics, spamming researchers with unsolicited emails and invitations to submit their work.

For a medtech researcher specifically, the consequences of publishing in a predatory journal extend beyond personal reputational damage. A clinical claim published in a predatory journal carries no credibility with regulatory bodies — the EMA, the CE marking notified body system, the FDA — and may actively undermine a regulatory submission that cites it. An investor conducting due diligence will identify publication venue as a signal of scientific credibility; a predatory journal citation in a pitch deck is a red flag that experienced life sciences investors recognise immediately. And once a paper is associated with a predatory venue, the retraction or disavowal process is more difficult, more public, and more damaging than simply not having published there in the first place.

A Practical Decision Framework

The publishing decision for a medtech or biotech result should be made before submission, not after. Here is a framework that accounts for cost, credibility, and strategic purpose simultaneously.

1. Establish your mandate obligations

   If your research was funded by Horizon Europe, the ISF, a national research council, or an institutional grant, identify the open access requirements and APC eligibility rules before selecting a journal. Do not assume hybrid journals are covered. Check the funder's policy directly.

2. Check institutional agreements

   Before paying any APC, check whether your institution has a read-and-publish agreement with the target publisher. The OpenAPC database maintains current data on institutional APC payments across European institutions. Israeli researchers can check their institution's library services for current publisher agreements.

3. Verify the journal

   For any journal outside your immediate familiar knowledge, use these tools in sequence: check the Directory of Open Access Journals (DOAJ) for inclusion; check the journal's presence in Scopus or Web of Science; run it through the Think.Check.Submit. checklist; and search Beall's List archive and the Predatory Journals database. Legitimate journals do not boast about ResearchGate inclusion or ISSNs as if these were prestigious databases — a consistent marker of predatory operations.

4. Consider the strategic purpose of the publication

   Not every result needs to appear in a $5,000 journal. A methodological validation, a negative result, or preliminary clinical data may be entirely appropriately published in PLOS ONE or a society journal at a fraction of the cost, and may reach a more relevant audience for its specific purpose. Reserve the high-APC publications for results where the venue's prestige directly serves a commercial or regulatory objective.

5. Use preprints strategically

   For results where priority establishment matters — where competitive timing is important — posting to bioRxiv or medRxiv before submission to a peer-reviewed journal is standard practice in the biotech community and costs nothing. It does not preclude subsequent peer-reviewed publication in any major journal and provides immediate visibility and a citable timestamp.

The Real Cost of Getting It Wrong

The APC at Nature Biomedical Engineering is €9,500. The APC at a predatory journal is perhaps €500. The cost of publishing in the wrong place — whether that means a predatory journal that destroys credibility, a hybrid journal whose APC your funder will not cover, or a legitimate journal whose audience does not include the investors and regulators you are trying to reach — is considerably higher than either number.

Publishing strategy in medtech is not an afterthought that follows scientific success. It is part of the commercial strategy — one of the earliest and most visible signals that the people who will fund, regulate, and adopt your technology will use to assess whether your science is as serious as you believe it is. Getting that signal right, at the right cost, in the right venue, for the right audience, is not a publishing question. It is a market positioning question. And it deserves the same rigour as every other decision in the commercialisation process.